ФАКТОРЫ ПРОГНОЗА ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1726-9776-2010-6-4-47-53
Аннотация
Рак предстательной железы широко распространен, и в настоящее время очевидной является гетерогенность этого заболевания. Постоянно идут поиски факторов, позволяющих предсказать неблагоприятное течение и биологическое различие опухолей. Коллегия американских патологов (College of American Pathologists) классифицировала известные в настоящее время прогностические факторы на 3 категории: I категория - факторы, прогностическая важность и успешное применение которых в практике доказаны; II - факторы, которые широко изучены биологически и клинически, но значимость которых требуется доказать в широких статистических исследованиях; III - все другие факторы, которые недостаточно изучены, чтобы продемонстрировать их прогностическую ценность. Широкое клиническое применение имеют прогностические факторы I категории, такие как уровень простатспецифического антигена, стадия TNM, градация Глисона и состояние хирургических краев. Факторы II категории не так широко используются в клинической практике. Ценность некоторых факторов III категории (биомаркеры р53, Ki-67, Bcl-2, рецепторы андрогенов) несомненна, и со временем они претендуют на широкое применение в клинической практике. Значение молекулярно-биологических маркеров для клиники требует дальнейшего изучения.
Список литературы
1. Buhmeida A., Pyrhönen S., Laato M., Collan Y. Prognostic factors in prostate cancer.Diagn Pathol 2006;3:1–4.
2. World Health Organization Classification of Tumours. Pathology & genetics: tumours of the urinary system and male genital organs. Lyon, France: IARC Press, 2004; p. 179–184.
3. Bostwick D.G., Grignon D.J., Hammond M.E. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7):995–1000.
4. Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16.
5. Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283–90.
6. Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239–46.
7. Hessels D., Klein Gunnewiek J.M.T., van Oort I. et al. DD3 (PSA3) – based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8–5; discussion 15–6.
8. Kattan M.W., Stapleton A.M.F., Wheeler T.M., Scardino P.T. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528–37.
9. Kattan M.W., Eastham J.A., Stapleton A.M. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.
10. Partin A.W., Kattan M.W., Subong E.N.P. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445–51.
11. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–8.
12. Sebo T.J., Ceville J.C., Riele D.L. et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. AJSP 2002:26(4):431–39.
13. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostate Carcinoma. Am J Surg Pathol 005;29:1228–42.
14. Petersen R.O., Sesterhenn I.A., Davis C.J. Urologic Pathology. Philadelphia: Lippincott Williams &Wilkins, 2008.
15. Yossepowich O., Bjartell A., Easthem J.A. et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87–99.
16. Epstain J.I., Amin M., Boccon-Gibot L. et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34–63.
17. Sofer M., Hamilton-Nelson K.L., Civantos F., Soloway M.S. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol 2002;167:2453–6.
18. Epstain J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582–93.
19. Pettus J.A., Weight C.J., Thompson C.J. et al. Biochemical failure in man following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004;172:129–32.
20. Bloom K.D., Richie J.P., Schultz D. et al. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004;64(2):333–6.
21. Debras B., Guillonneau B., Bougaran J. et al. Prognostic significant of eminal vesicles invasion on the radical prostatectomy specimen. Rationale for seminal vesicles biopsies. Eur Urol 1998;33:271–7.
22. McNeal J.E., Villers A.A., Redwine E.A. et al. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990;14:240–7.
23. Epstain J.I., Carmichael M., Partin A.W., Walsh P.C. Is tumour volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage III B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478–81.
24. Bostwick D.G., Graham S.D., Napalcov P. et al. Staging of early prostate cancer: a proposed tumour volume-based prognostic index. Urology 1993;41:403–11.
25. Quinn D.I., Henshall S.M., Sutherland R.L. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858–87.
26. Bettencourt M.C., Bauer J.J., Sesterhenn I.A. et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064–8.
27. Bubendorf L., Sauter G., Moch H. et al. Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Path 1996;178:437–41.
28. Aaltomaa S., Lipponen P., Vesalainen S. et al. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;3:2410–5.
29. Thomas D.J., Robinson M., King P. et al. p53 expression and clinical outcome in prostate cancer. Br J Urol 1993;72:778–81.
30. Shurbaji M.S., Kalbfleisch J.H., Thormond T.S. Immunohistochemical detection of p53 protein as prognostic indicator in prostate cancer. Hum Pathol 995;26:106–9.
31. Papadopoulos I., Rudolph P., Wirth B., Weichert J.K. P53 expression, proliferation marker Ki-67. DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology 1996;48:261–8.
32. Revelos K., Petraki C., Gregorakis A. et al. Immunohistochemical expression of Bcl-2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 2005;25(4):3123–33.
33. Fleishman A., Schlomm T., Huland H. et al. Tissue microarray of prostate cancer: successful survival stratification based on the heterogeneously distributed tumor markers Bcl-2 and Ki-67. Virchows Arch 2009;455:229.
34. Moul J.W., Bettencourt M.C., Sesterhenn I.A. et al. Protein expression of p53, Bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159–66.
35. Theodorescu D., Broder S.R., Boyd J.C. et al. p53, Bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158:131–7.
36. Grignon D.J., Caplan R., Sarkar F.H. et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158–65.
37. Stattin P., Westin P., Damber J.E. et al. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer 1998;77:670–5.
38. Che M.D., De Silvio M., Pollac A. et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. J Radiat Oncol 2007;69:1117–23.
39. Scherr D.S., Vaughan E.D., Wei J. et al. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999;162:12–6.
40. Wilson C.M., Griffin J.E., Wilson J.D. et al. Immunoreactive androgen receptor expression in subgects with androgen resistence. J Clin Endocrinol Metab 1992;75:1474–8.
41. Sweat S.D., Pacelli A., Bergstralh E.G. Androgen receptor expression in prostate intraepithelial neoplasia and cancer. J Urol 1999;161:1229–32.
Рецензия
Для цитирования:
Горбань Н.А., Карякин А.О. ФАКТОРЫ ПРОГНОЗА ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2010;6(4):47-53. https://doi.org/10.17650/1726-9776-2010-6-4-47-53
For citation:
Gorban N.A., Karyakin A.O. PROGNOSTIC FACTORS IN PROSTATE CANCER. Cancer Urology. 2010;6(4):47-53. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-4-47-53
Просмотров: 685
Послать статью по эл. почте 
